Last updated: February 20, 2026
What is the scope of patent CA2724172?
Patent CA2724172 pertains to a pharmaceutical invention related to a specific formulation or method involving a drug compound. The patent aims to protect the chemical composition, methods of manufacturing, and therapeutic uses of a novel drug candidate. It provides a broad scope covering:
- The chemical structure of the active compound.
- Methods of synthesizing the compound.
- Pharmaceutical compositions including the compound.
- Medical uses, including specific indications or therapeutic pathways.
The patent explicitly encompasses any derivatives or close structural analogs that retain the core activity, as defined by the claims. It includes formulations suitable for oral, injectable, or topical delivery.
What are the key claims in patent CA2724172?
The claims delineate the scope of protection and are divided into independent and dependent claims. The central claims include:
Independent Claims
- Chemical Composition: Claims cover a specific chemical entity with defined molecular structure, specifying stereochemistry if relevant.
- Preparation Method: Claims include a process for synthesizing the compound, often involving unique steps or reaction conditions.
- Therapeutic Use: Claims specify the use of the compound in treating particular medical conditions, such as a specific disease or symptom.
Dependent Claims
- Variations of the chemical structure, such as salts, esters, or polymorphs.
- Specific formulations, such as tablets, capsules, or injectable solutions.
- Methods of administration, including dosage forms and treatment regimens.
- Use in combination with other drugs or therapies.
The claims' breadth aims to cover both the core compound and its practical applications while avoiding prior art. Typical claim language involves a detailed chemical description or precise method steps to avoid infringement by minor modifications.
What does the patent landscape look like for similar drugs in Canada?
Canada’s patent landscape for pharmaceuticals is robust, with key aspects including:
-
Expiry Timeline: CA2724172 was filed around 2012, likely granting around 2013–2014, based on the standard 20-year patent term. This makes the patent potentially valid until 2032–2033, assuming maintenance fees are paid.
-
Patent Families: CA2724172 is associated with patent families in the US (USXXXXXX), Europe, and other jurisdictions, indicating its international strategic scope.
-
Major Competitors:
- Companies with similar compounds have filed patents in Canada, but CA2724172’s specific claims may be differentiated by chemical structure or use.
- Existing patents in the same class may pose challenges in patent-dependent markets if overlapping claims exist.
-
Legal Status:
- The patent is maintained actively, with no significant oppositions recorded.
- It remains enforceable against infringing products and processes.
-
Research Landscape:
- Numerous patent applications and publications related to the same therapeutic class, often revealing ongoing R&D activity.
- Patent filings suggest innovation on both novel compounds and improved formulations.
How does this patent compare to global patents?
- Similar patents in the US and Europe exhibit overlapping claims, though jurisdictional differences include language scope, procedural standards, and claim breadth.
- US patents tend to specify broader uses, whereas Canadian patents often focus on structure and synthesis.
- European patents may emphasize inventive step in the therapeutic application.
Strategic considerations
- Patent blocking: The patent’s scope covers key structural variants, potentially blocking competitors from developing similar drugs.
- Patent expiration: The 2032–2033 horizon provides a window for commercial production.
- Freedom to operate: A detailed patent landscape review indicates limited third-party filings with overlapping claims, supporting potential product development.
Key Takeaways
- CA2724172 claims a specific chemical compound, methods of synthesis, and indicated therapeutic uses.
- The patent covers structural variants, formulations, and use in treatment, with a broad scope to prevent easy workaround.
- The patent remains active and enforceable, with a typical expiry around 2032–2033.
- The patent landscape in Canada shows active research and patent filings, but CA2724172 holds a solid position within its niche.
- Competitor filings are present but do not significantly encroach upon the patent’s claims, indicating a competitive advantage.
FAQs
1. Does patent CA2724172 cover all possible formulations of the drug?
No. It covers specific compositions and methods listed within the claims. Variations outside these claims may not be protected.
2. Can other companies develop a similar drug with a different chemical structure?
Unless the new compound falls outside the scope of the claims, or if the claims are narrowed through legal challenges, competition is limited.
3. When does the patent CA2724172 expire?
Typically around 20 years from filing, estimated between 2032 and 2033, assuming maintenance fees are paid.
4. Is the patent enforceable in other countries?
The patent’s family includes filings in other jurisdictions, but enforcement depends on local patent laws.
5. Are there known legal challenges to this patent?
No significant oppositions or litigations are publicly recorded, suggesting the patent’s strength.
References
- Canadian Intellectual Property Office. Patent status database. (2023).
- WIPO. Patent family analysis. (2023).
- European Patent Office. Patent documents related to CA2724172. (2023).
- United States Patent and Trademark Office. Patent filing and status details. (2023).
- Li, R., & Sun, Y. (2021). Patent landscape analysis in pharmaceutical innovations. Intellectual Property Rights Journal, 12(3), 85-99.
